Alto NeurosciencevsMerck & Company

ANRO and MRK stock compared: price, dividend, valuation and results, from SEC filings.

ANRO

Alto Neuroscience, Inc.

$25.37

Value $1.0B

-4.30%
ANRO's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Alto Neuroscience (ANRO) has a market value of $1.0B and Merck & Company (MRK) $331B. Over the last year, with dividends, ANRO moved +63.3% and MRK +44.8%. Dividend yield: ANRO none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ANRO$1.0B

    MRK$331B

    MRK is 325 times ANRO

  • Revenue, 12 months

    ANRO–

    MRK$67.4B

  • Net income, 12 months

    ANRO-$95M

    MRK$2.5B

  • Operating margin

    ANRO–

    MRK–

  • ROIC

    ANRO-31.2%

    MRK3.9%

    35.1 points apart

  • P/E

    ANRO–

    MRK134.8

  • Dividend yield

    ANRO0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ANRO+63.3%

MRK+44.8%

100150200DecFebAprJunAugOct
Returns by period
PeriodANROWith dividendsMRKWith dividends
1 year since November 19, 2025+63.3%Price +63.3%+44.8%Price +40.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ANROAlto NeuroscienceMRKMerck & Company

Valuation

ANROMRK
Valuation
Price$25.37$133.72
Market value$1.0B$331B
Enterprise value (EV)–$375B
P/E–134.8
P/E, 5-year median–14.8
P/B3.47.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

ANROMRK
Results and growth
Revenue, 12 months–$67.4B
Net income, 12 months-$95M$2.5B
Free cash flow, 12 months-$80M$14.7B
Earnings per share, 12 months-$2.44$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

ANROMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin–3.6%
ROIC-31.2%3.9%
ROE-46.6%5.2%

Balance sheet

ANROMRK
Balance sheet
Cash$319M$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover-32.0×2.4×

Dividends and buybacks

ANROMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ANRO or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Alto Neuroscience or Merck & Company?

By market value, Merck & Company ($331B) is about 324.9 times Alto Neuroscience ($1.0B), at today's prices.

How did ANRO and MRK stock do over the last 1 years?

Since November 19, 2025, ANRO's price moved +63.3% and MRK's +40.7%. With dividends: ANRO +63.3% (+63.3% a year), MRK +44.8% (+44.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, ANRO or MRK?

The dividend yield at today's price is none for Alto Neuroscience and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which is the better investment, Alto Neuroscience or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.